… challenging to interpret because tumors often shrink slowly … tumor cell death in real time
by quantifying changes in circulating tumor DNA (ctDNA) levels could enable early assessment …

Circulating tumor DNA holds substantial promise as an early detection biomarker, particularly
for cancers that do not have currently accepted screening methodologies, such as ovarian, …

… tumor change over time. One approach to identifying the spatial and temporal complexity of
tumors is the analysis of tumor DNA … multiple mutations to assess whether specific mutations, …

… The ability to assess the presence, level, and composition of tumor DNA from a routine,
noninvasive blood draw has opened the door to a broad array of high-impact clinical applications…

… tumor DNA (ctDNA) has demonstrated great potential as a noninvasive biomarker to assess
minimal residual disease (MRD) and profile tumor … during and after tumor resection, or its …

… Treatment response assessment for patients with advanced solid tumors is complex and …
circulating tumor DNA (ctDNA) were used to assess response or resistance to treatment early in …

… Purpose: Noninvasive drug biomarkers for the early assessment of tumor response can enable
… Circulating tumor DNA (ctDNA) is released into the circulation by tumor cell turnover and …

… For each patient, one tumor mutation was selected to assess the presence and the level
of ctDNA in plasma samples using a digital genomic assay termed Safe-SeqS. …

… circulating tumor allele fraction (cTAF)], which could inform prognosis and help assess the
cancer's clinical significance. This review discusses the factors affecting circulating tumor DNA …

… Circulating tumor DNA (ctDNA) is free DNA shed from tumor … High concordance between
ctDNA and tumor DNA plays a … be applied in early diagnosis and can be used to assess the …